Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 150 participants.
Also called NCT05598333
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 150 participants
- Sponsor
- AskBio Inc
- Registry
-
NCT05598333
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Austria, Belgium, Bulgaria, Canada, Germany, Hungary, Netherlands, Poland, Romania, Spain, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05598333. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-20 (actual); primary completion 2026-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
- Acronym
- GenePHIT
- Condition
- Congestive Heart Failure
- Intervention (Drug)
- AB-1002
- Lead sponsor
- AskBio Inc
Record details
- Record id
cardio:ct-nct05598333- Content hash
39652e33fd0a6577d84c6f4dadf756b3289b80dc6aa50cd3ee603bfe885f425c